DUSA Pharmaceuticals signs agreement with Richard Wolf Medical Instruments re: Levulan Photodiagnosis of bladder cancer.TORONTO--(BUSINESS WIRE)--May 20, 1997--DUSA Pharmaceuticals, Inc. (NASDAQ NASDAQ in full National Association of Securities Dealers Automated Quotations U.S. market for over-the-counter securities. Established in 1971 by the National Association of Securities Dealers (NASD), NASDAQ is an automated quotation system that reports on NMS See NetWare Management System. : DUSA DUSA Deputy Under Secretary of the Army DUSA Deakin University Student Association DUSA Dundee University Students' Association (Scotland) DUSA Designated Unclassified Subject Area ) announced today the signing of an agreement with Richard Wolf Medical Instruments Corp., Vernon Hills, Illinois Vernon Hills is a village in Lake County, Illinois, United States. The population was 20,120 at the 2000 census, and estimated to be 23,957 as of 2005. Vernon Hills serves as a retail hub for its surrounding area (Libertyville, Lake Forest, Mundelein, Lincolnshire). , to collaborate on the development of DUSA's Levulan (ALA) Photodiagnosis (PD) for enhanced detection of bladder cancer. Under the agreement, Wolf will provide, at no cost to DUSA, proprietary non-laser light sources and cystoscopes (instruments for visualizing the bladder), along with technical and regulatory support, for DUSA's upcoming Phase I/II clinical trials. These trials will examine the use of Levulan PD to enhance the visual detection of bladder cancer. In return, DUSA plans to seek regulatory approval for the Wolf light sources to be used with Levulan in this indication(1). If and when DUSA achieves FDA FDA abbr. Food and Drug Administration FDA, n.pr See Food and Drug Administration. FDA, n.pr the abbreviation for the Food and Drug Administration. approval for Levulan PD of bladder cancer in the U.S., the companies plan to co-operate in the marketing of the system, with the intention that DUSA will retain the revenues from Levulan sales, while Wolf will retain the revenue from device sales(1). Under the agreement, DUSA reserves the right to qualify other manufacturers' light sources/cystoscopes with the FDA for use in Levulan(TM) PD of bladder cancer. Richard Wolf Medical Instruments Corp. is a wholly owned subsidiary Wholly Owned Subsidiary A subsidiary whose parent company owns 100% of its common stock. Notes: In other words, the parent company owns the company outright and there are no minority owners. of Richard Wolf GmbH, a large, privately held, multi-national German corporation that is a leader in devices for endoscopy endoscopy Examination of the body's interior through an instrument inserted into a natural opening or an incision, usually as an outpatient procedure. Endoscopes include the upper gastrointestinal endoscope (for the esophagus, stomach, and duodenum), the colonoscope (for the , the basis for all minimally invasive therapy. Richard Wolf and its worldwide offices manufacture and market endoscopes, accessory instrumentation, and video imaging systems to diagnostic and surgical specialists throughout the world. The planned DUSA study is based on independent European human clinical studies which demonstrated that ALA PD can increase the ability to detect bladder cancers during cystoscopy Cystoscopy Definition Cystoscopy (cystourethroscopy) is a diagnostic procedure that is used to look at the bladder (lower urinary tract), collect urine samples, and examine the prostate gland. by approximately 20%. An estimated 800,000-900,000 cystoscopies are performed each year in the U.S. alone for the diagnosis and/or detection of bladder cancer. D. Geoffrey Shulman, MD, DUSA President and CEO (1) (Chief Executive Officer) The highest individual in command of an organization. Typically the president of the company, the CEO reports to the Chairman of the Board. , stated "Levulan(TM) PD for enhanced detection of bladder cancer may represent a significant advance in the management of this potentially fatal condition(1). DUSA is delighted to be collaborating on this important indication with Richard Wolf, a world leader in high quality light sources and endoscopic instruments. With the agreement in place, DUSA intends to move quickly to file an IND, and begin the clinical trials as soon as possible(1)." Robert Casarsa, Richard Wolf Quality Assurance Manager, stated "We are pleased to be a participant in DUSA's upcoming clinical trials. Richard Wolf's 90 year history has its roots in urology and this collaboration with DUSA will open a promising market for the company's instrumentation." DUSA Pharmaceuticals, Inc. is a development stage pharmaceutical company engaged primarily in the development of light-activated Levulan PDT PDT abbr. Pacific Daylight Time PDT Pacific Daylight Time PDT n abbr (US) (= Pacific Daylight Time) → hora de verano del Pacífico PDT and PD for multiple therapeutic or diagnostic medical indications. DUSA is a world leader in topically or locally applied PDT and PD. The Company is incorporated in New Jersey, with executive offices in Toronto, Ontario, and R&D administration in Tarrytown, New York Tarrytown is a village in Westchester County, New York, United States. The population was 11,090 at the 2000 census. The Village of Tarrytown is located in the northwest part of the Town of Greenburgh, New York. . Except for historical information, this news release contains certain forward-looking statements that involve risk and uncertainties, which may cause actual results to differ materially from the statements made. Such factors include, but are not limited to, changing market conditions, the progress of clinical trials and the results obtained, the establishment of new corporate alliances, the impact of competitive products and pricing, the timely development of light devices for several indications, FDA approval and market acceptance of the Company's products, and other risks detailed from time to time in the Company's United States Securities and Exchange Commission (SEC) filings. These statements are marked by (1). CONTACT: DUSA Pharmaceuticals, Inc. D. Geoffrey Shulman, 416.363.5059 or Sunrise Financial Group Derek Caldwell, 212.421.1616 |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion